Pharmacology, Toxicology and Pharmaceutical Science
Immunotherapy
87%
Malignant Neoplasm
67%
Chimeric Antigen Receptor
37%
Interleukin 2
33%
Solid Malignant Neoplasm
25%
Clinical Trial
25%
Head and Neck Squamous Cell Carcinoma
25%
Neoplasm
18%
Integrin
16%
Acute Myeloid Leukemia
16%
Cancer Epidemiology
16%
Cytarabine
16%
Cytokine
16%
Adverse Event
15%
Antitumor Activity
13%
Hematologic Malignancy
12%
Diseases
10%
Interleukin 4
10%
Prostaglandin E Receptor
8%
Tumor Model
8%
Prostaglandin E Receptor 2
8%
Overall Survival
5%
Oncolytic Virus
5%
Dimer
5%
Chill
5%
Carcinoma
5%
Pembrolizumab
5%
Lymphocytopenia
5%
Talimogene Laherparepvec
5%
Cytokine Receptor
5%
Biochemistry, Genetics and Molecular Biology
T Cell
100%
Chimeric Antigen Receptor
50%
Interleukin 2
33%
Interleukin 4
29%
Cytokine Receptor
27%
ErbB
25%
Cancer Immunotherapy
21%
Antineoplastic Activity
18%
Cancer Cell
16%
Integrin
16%
Cytarabine
16%
Cytokine Release
16%
Myeloid
16%
Sensitization
16%
Prostaglandin E2 Receptor
8%
Prostaglandin E
8%
Axenic Culture
5%
Cytokine
5%
Retrovirus
5%
Clinical Trial
5%
Immunology and Microbiology
T Cell
75%
Adoptive Immunotherapy
50%
Interleukin 2
33%
Cytokine Receptor
25%
Interleukin 4
25%
Chimeric Antigen Receptor T-Cell
25%
Cancer Immunotherapy
22%
Chimeric Antigen Receptor
18%
Sensitization
16%
Cytokine Release
16%
Antineoplastic Activity
16%
Cancer Cell
16%
Integrin
16%
Myeloid
16%
Prostaglandin E2
8%
Prostaglandin E
8%
Retrovirus
6%
Cytokine
6%
Axenic Culture
6%
Neck
6%
